IJ Pharmaceutical Research
Crossref
1.
2. Large-Scale Purification and Characterization of Recombinant Receptor-Binding Domain (RBD) of SARS-CoV-2 Spike Protein Expressed in Yeast
- Gaurav Nagar
- Siddharth Jain
- Meghraj Rajurkar
- Rakesh Lothe
- Harish Rao
- Sourav Majumdar
- Manish Gautam
- Sergio A. Rodriguez-Aponte
- Laura E. Crowell
- J. Christopher Love
- Prajakta Dandekar
- Amita Puranik
- Sunil Gairola
- Umesh Shaligram
- Ratnesh Jain
3. Controlling the Quality of Nanodrugs According to Their New Property—Radiothermal Emission
- Gleb V. Petrov
- Daria A. Galkina
- Alena M. Koldina
- Tatiana V. Grebennikova
- Olesya V. Eliseeva
- Yana Yu. Chernoryzh
- Varvara V. Lebedeva
- Anton V. Syroeshkin
4. Viral protein-based nanoparticles (part 2): Pharmaceutical applications
- Rocio Mellid-Carballal
- Sara Gutierrez-Gutierrez
- Carmen Rivas
- Marcos Garcia-Fuentes
5. A substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicity
- Yuhan Li
- Xianwen Zhang
- Wanbo Tai
- Xinyu Zhuang
- Huicheng Shi
- Shumin Liao
- Xinyang Yu
- Rui Mei
- Xingzhao Chen
- Yanhong Huang
- Yubin Liu
- Jianying Liu
- Yang Liu
- Yibin Zhu
- Penghua Wang
- Mingyao Tian
- Guocan Yu
- Liang Li
- Gong Cheng
6. Modularized viromimetic polymer nanoparticle vaccines (VPNVaxs) to elicit durable and effective humoral immune responses
- Zichao Huang
- Xinyu Zhuang
- Liping Liu
- Jiayu Zhao
- Sheng Ma
- Xinghui Si
- Zhenyi Zhu
- Fan Wu
- Ningyi Jin
- Mingyao Tian
- Wantong Song
- Xuesi Chen
7. Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for Vaccines
- Nelli S. Khudainazarova
- Dmitriy L. Granovskiy
- Olga A. Kondakova
- Ekaterina M. Ryabchevskaya
- Angelina O. Kovalenko
- Ekaterina A. Evtushenko
- Marina V. Arkhipenko
- Nikolai A. Nikitin
- Olga V. Karpova
8. Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
- Monrat Chulanetra
- Primana Punnakitikashem
- Kodchakorn Mahasongkram
- Wanpen Chaicumpa
- Kantaphon Glab-ampai
9. COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic
- Aleksandra Anna Zasada
- Aniela Darlińska
- Aldona Wiatrzyk
- Katarzyna Woźnica
- Kamila Formińska
- Urszula Czajka
- Małgorzata Główka
- Klaudia Lis
- Paulina Górska
10. Tuning the tropism and infectivity of SARS-CoV-2 virus-like particles for mRNA delivery
- Qi Yang
- Bruce A Davidson
- Petar Pajic
- Xuyang Chen
- Omer Gokcumen
- Min Gao
- Sriram Neelamegham
11. mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions
- Ryo Okuyama
12. A Critical Assessment of COVID-19 Genomic Vaccines
- Dima A. Sabbah
- Rima Hajjo
- Suhair Sunoqrot
13. Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial
- Bei-Fang Yang
- Jing Jin
- Xi-Ran He
- Zhong-Hua Yang
- Xiao’ai Qian
- Ye-Qing Tong
- Chang-Xian Ke
- Zhao-Hong Li
- Zhao-Xia Li
- Lin-Feng Zhong
- Ze-Hong Gan
- Xian-Feng Zhang
- Ying Zeng
14. Simian Immunodeficiency Virus-Based Virus-like Particles Are an Efficient Tool to Induce Persistent Anti-SARS-CoV-2 Spike Neutralizing Antibodies and Specific T Cells in Mice
- Alessandra Gallinaro
- Chiara Falce
- Maria Franca Pirillo
- Martina Borghi
- Felicia Grasso
- Andrea Canitano
- Serena Cecchetti
- Marco Baratella
- Zuleika Michelini
- Sabrina Mariotti
- Maria Vincenza Chiantore
- Iole Farina
- Antonio Di Virgilio
- Antonella Tinari
- Gabriella Scarlatti
- Donatella Negri
- Andrea Cara
15. A perspective on SARS-CoV-2 virus-like particles vaccines
- Xiaoyang Gao
- Yeting Xia
- Xiaofang Liu
- Yinlan Xu
- Pengyang Lu
- Zhipeng dong
- Jing Liu
- Gaofeng Liang
16. An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines
- Doddy Irawan Setyo Utomo
- Hamizah Suhaimi
- Nor Azila Muhammad Azami
- Fazren Azmi
- Mohd Cairul Iqbal Mohd Amin
- Jian Xu
17. An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines
- Dona Susan Mathew
- Tirtha Pandya
- Het Pandya
- Yuzen Vaghela
- Selvakumar Subbian
18. Inducing Long Lasting B Cell and T Cell Immunity Against Multiple Variants of SARS‐CoV‐2 Through Mutant Bacteriophage Qβ—Receptor Binding Domain Conjugate
- Zibin Tan
- Canchai Yang
- Po‐han Lin
- Sherif Ramadan
- Weizhun Yang
- Zahra Rashidi
- Shuyao Lang
- Fatemeh Shafieichaharberoud
- Jia Gao
- Xingling Pan
- Nachy Soloff
- Xuanjun Wu
- Steven Bolin
- Dohun Pyeon
- Xuefei Huang
19. Platforms, advances, and technical challenges in virus-like particles-based vaccines
- Reeshu Gupta
- Kajal Arora
- Sourav Singha Roy
- Abyson Joseph
- Ruchir Rastogi
- Nupur Mehrotra Arora
- Prabuddha K. Kundu